PrEP Seguro: Antiretroviral-based HIV Prevention Among Men at High Risk in Mexico
Primary Purpose
HIV Infections
Status
Completed
Phase
Not Applicable
Locations
Mexico
Study Type
Interventional
Intervention
Conditional Economic Incentive (CEI)
Sponsored by

About this trial
This is an interventional prevention trial for HIV Infections focused on measuring adherence, AIDS prevention, Anti-Retroviral Agents, Behavioral Economics, Biological Markers, Cost-effectiveness, MSM, HIV Prevention, PrEP
Eligibility Criteria
Inclusion Criteria:
- Male at birth and self-identifies as male at the time of enrollment
- At least 18 years of age
- Has tested negative for HIV in the past month
- Demonstrates high risk of HIV acquisition defined as having had sex with penetration (oral or anal) with at least 8 male partners in past six months
- Has exchanged or accepted money, drugs or gifts in exchange for sex on at least 8 occasions in the past month
- Willing and capable of providing blood and scalp hair samples for assessments
- Willing and able to provide written informed consent
- Have successfully initiated PrEP and are returning for their second bottle of PrEP pills
- Able to provide a home address or personal telephone number, or able to provide two personal contacts who will be able to know the patient's whereabouts during the study period
Exclusion Criteria
- Under 18 years of age
- Unable to give informed consent due to severe mental or physical illness/substance intoxication at baseline visit
- Presents with severe adverse reactions to PrEP
- The subject will be excluded from the study at his own request for any reason since participation is voluntary
Sites / Locations
- National Institute of Public Health (INSP) / Clinica Condesa
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
CEI Group
SOC Group
Arm Description
CEI Group will receive the standard of care (information, prescription, free PrEP) and economic incentives contingent on sufficiently-high adherence to PrEP.
SOC Group will receive the standard of care only (information, prescription, free PrEP.)
Outcomes
Primary Outcome Measures
ARV Hair Concentrations
Level of ARV (TDF/FTC) in scalp hair samples
Secondary Outcome Measures
Clinic attendance/retention
This is a measure of retention in care. As each participant finishes his 6-month study period, retention will be determined by number of quarterly care visits completed.
Medication adherence
Medication Possession Ratio (MPR) is defined as the number of dispensed pills divided by the number of days between visits which will be derived from pharmacy refill records
Questionnaire to Assess Self-reported PrEP Use
Self report adherence to assess for change in adherence.
Reduction in HIV and STI incidence relative to control group
Male sex worker participants will be tested at baseline and 6-month follow-up for HIV and syphilis. Incidence rates for all infections at 6-month follow-up will be compared between the conditional economic incentive (CEI) group and the standard of care (SOC) group.
Reduction in number of unprotected sex acts relative to control group
Male sex worker participants will be assessed at baseline and 6-month follow-up using self-report measures of frequency of protected and unprotected sex acts with clients. Changes in frequency at 6-month follow-up will be compared between the conditional economic incentive (CEI) group and the standard of care (SOC) group.
Full Information
NCT ID
NCT03674983
First Posted
August 10, 2018
Last Updated
July 25, 2023
Sponsor
Brown University
Collaborators
National Institute of Mental Health (NIMH), Consorcio de Investigación sobre VIH/SIDA/TB (CISIDAT)., University of California, San Francisco, Mexican National Institute of Public Health
1. Study Identification
Unique Protocol Identification Number
NCT03674983
Brief Title
PrEP Seguro: Antiretroviral-based HIV Prevention Among Men at High Risk in Mexico
Official Title
PrEP Seguro: Antiretroviral-based HIV Prevention Among Men at High Risk in Mexico
Study Type
Interventional
2. Study Status
Record Verification Date
July 2023
Overall Recruitment Status
Completed
Study Start Date
May 15, 2019 (Actual)
Primary Completion Date
August 30, 2021 (Actual)
Study Completion Date
August 30, 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Brown University
Collaborators
National Institute of Mental Health (NIMH), Consorcio de Investigación sobre VIH/SIDA/TB (CISIDAT)., University of California, San Francisco, Mexican National Institute of Public Health
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The objective of this R34 application is to prepare for testing innovative user-centered ways to promote PrEP adherence at scale. Our central hypothesis is that adherence to PrEP can be improved among MSW if PrEP is provided for free along with highly-tailored conditional economic incentives (CEI). The specific aims are: Aim 1: To refine the design of PrEP adherence intervention with user-centered conditional economic incentives to maximize sustained adherence behaviors through a user-responsive computerized survey (n=200). We incorporate quantitatively identified preferences for CEIs through a user- responsive computerized survey. We use conjoint analysis to understand preferences for CEI intervention components and how CEIs should be integrated into an optimal combination package to be tested in Aim 2. Aim 2: Measure the extent to which a user-centered CEI intervention can help MSW increase their adherence to free PrEP in a randomized controlled pilot (n=100). Among MSW who accept to take free PrEP, and return at month 1 for a second pill bottle, we will randomize n=100 MSW to either: standard of care (SoC: information, prescription, free PrEP) or CEI (SoC + incentives contingent on sufficiently-high adherence to PrEP). We will assess the primary outcome (biomarker of adherence using scalp hair analysis) at months 3 and 6, as well as secondary outcomes: clinic attendance/retention, medication possession ratio, self-reported PrEP use, and sexual behavioral disinhibition (number of partners, condom use, incident STI). Aim 3: Estimate the preliminary cost-effectiveness of incentives for PrEP adherence to maximize future policy and practice relevance of this promising intervention strategy. Our working hypothesis is that conditional economic incentives for PrEP adherence will be cost-effective in terms of cost per fully- adherent month on PrEP, cost per HIV infection averted, and cost per disability-adjusted life year saved when compared to controls not receiving the conditional incentives. The expected outcome of this R34 is a demonstration that is feasible to implement user-centered CEIs in this context, as well as preliminary efficacy and cost-effectiveness data. The project will have positive impact because it is a critical step toward scaled-up implementation of PrEP in this highly-at-risk population of MSWs in Mexico, with implications for other concentrated epidemics among MSW worldwide.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV Infections
Keywords
adherence, AIDS prevention, Anti-Retroviral Agents, Behavioral Economics, Biological Markers, Cost-effectiveness, MSM, HIV Prevention, PrEP
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Aim 1: discrete choice experiment (DCE) with n=200. Aim 2: randomly assign 100 HIV-negative MSW in a 1:1 ratio either to: the SoC group, or to the CEI group. MSW in the SoC group (n=50) will receive transport reimbursement at baseline, 3 and 6 months. MSW in the CEI group (n=50) will receive transport reimbursement at baseline, 3 and 6 months, and additional incentives based on sufficiently high PrEP adherence at months 3 and 6. All participants will provide hair samples and have optional brief counseling based on hair sample results. Those in the CEI group, will receive additional incentives if concentrations of TDF/FTC in hair samples corroborate that they have been sufficiently adherent in recent weeks. The final incentives (amounts, format, location, etc.) will be based on Aim 1 results. 1-2 weeks after study visits, participants will receive a grade depending on the drug level detected in their scalp hair. The CEI amounts will be distributed depending on grade.
Masking
InvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
310 (Actual)
8. Arms, Groups, and Interventions
Arm Title
CEI Group
Arm Type
Experimental
Arm Description
CEI Group will receive the standard of care (information, prescription, free PrEP) and economic incentives contingent on sufficiently-high adherence to PrEP.
Arm Title
SOC Group
Arm Type
No Intervention
Arm Description
SOC Group will receive the standard of care only (information, prescription, free PrEP.)
Intervention Type
Behavioral
Intervention Name(s)
Conditional Economic Incentive (CEI)
Intervention Description
If hair testing shows that a participant has taken PrEP pills about 5-7 times in the previous week, he will receive a grade "A"; if he has taken PrEP pills about 3-4 times in the previous week he will receive a grade "B"; and if he has taken PrEP pills only 2 times or less, he will receive a grade "C". For those in the CEI group, if participant gets an A, he receives two additional prizes; if he gets a B, he receives one additional prize; and if he gets a C, he receives no additional prizes.
Primary Outcome Measure Information:
Title
ARV Hair Concentrations
Description
Level of ARV (TDF/FTC) in scalp hair samples
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Clinic attendance/retention
Description
This is a measure of retention in care. As each participant finishes his 6-month study period, retention will be determined by number of quarterly care visits completed.
Time Frame
6 months
Title
Medication adherence
Description
Medication Possession Ratio (MPR) is defined as the number of dispensed pills divided by the number of days between visits which will be derived from pharmacy refill records
Time Frame
6 months
Title
Questionnaire to Assess Self-reported PrEP Use
Description
Self report adherence to assess for change in adherence.
Time Frame
6 months
Title
Reduction in HIV and STI incidence relative to control group
Description
Male sex worker participants will be tested at baseline and 6-month follow-up for HIV and syphilis. Incidence rates for all infections at 6-month follow-up will be compared between the conditional economic incentive (CEI) group and the standard of care (SOC) group.
Time Frame
6 months
Title
Reduction in number of unprotected sex acts relative to control group
Description
Male sex worker participants will be assessed at baseline and 6-month follow-up using self-report measures of frequency of protected and unprotected sex acts with clients. Changes in frequency at 6-month follow-up will be compared between the conditional economic incentive (CEI) group and the standard of care (SOC) group.
Time Frame
6 months
10. Eligibility
Sex
Male
Gender Based
Yes
Gender Eligibility Description
Male
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Male at birth and self-identifies as male at the time of enrollment
At least 18 years of age
Has tested negative for HIV in the past month
Demonstrates high risk of HIV acquisition defined as having had sex with penetration (oral or anal) with at least 8 male partners in past six months
Has exchanged or accepted money, drugs or gifts in exchange for sex on at least 8 occasions in the past month
Willing and capable of providing blood and scalp hair samples for assessments
Willing and able to provide written informed consent
Have successfully initiated PrEP and are returning for their second bottle of PrEP pills
Able to provide a home address or personal telephone number, or able to provide two personal contacts who will be able to know the patient's whereabouts during the study period
Exclusion Criteria
Under 18 years of age
Unable to give informed consent due to severe mental or physical illness/substance intoxication at baseline visit
Presents with severe adverse reactions to PrEP
The subject will be excluded from the study at his own request for any reason since participation is voluntary
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Omar Galarraga, PhD
Organizational Affiliation
Brown University
Official's Role
Principal Investigator
Facility Information:
Facility Name
National Institute of Public Health (INSP) / Clinica Condesa
City
Mexico City
State/Province
DF
Country
Mexico
12. IPD Sharing Statement
Plan to Share IPD
No
IPD Sharing Plan Description
Materials generated under this project will be disseminated according to University and NIH policies regarding data sharing. Aggregate-level data collected in this collaboration will ultimately be available for public use. Opportunities for secondary analyses will be available following completion of the three-year project and publication of the main study findings. These findings will be available to the public through scientific meetings and peer-reviewed journals, as well as through a structured policy dissemination process.
Citations:
PubMed Identifier
34453239
Citation
Salinas-Rodriguez A, Sosa-Rubi SG, Chivardi C, Rodriguez-Franco R, Gandhi M, Mayer KH, Operario D, Gras-Allain N, Vargas-Guadarrama G, Galarraga O. Preferences for Conditional Economic Incentives to Improve Pre-exposure Prophylaxis Adherence: A Discrete Choice Experiment Among Male Sex Workers in Mexico. AIDS Behav. 2022 Mar;26(3):833-842. doi: 10.1007/s10461-021-03443-1. Epub 2021 Aug 27.
Results Reference
background
Learn more about this trial
PrEP Seguro: Antiretroviral-based HIV Prevention Among Men at High Risk in Mexico
We'll reach out to this number within 24 hrs